SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Praetorian Acquisition Corp. - Ordinary Shares - Class A

Investors are closely monitoring Praetorian Acquisition Corp. following its recent public debut as the market evaluates the potential for future merger and acquisition activity from the newly formed blank check company.

Bakkt, Inc. is building the backbone of next-generation financial infrastructure. The company provides solutions that enable institutional participation in the digital asset economy, spanning Bitcoin, tokenization, stablecoin payments, and AI-driven finance. Bakkt was founded in 2018 and is headquartered in New York, NY.

Bakkt Inc. - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt is trending as investors react to a 31.5% stake acquisition of Distributed Technologies Research, a move that has fueled intense community debate over potential dilution versus strategic expansion into AI-driven finance. Traders are also closely watching the ticker's high beta to Bitcoin, with many speculating on upcoming announcements at the company's investor day as they weigh the stock's long-term potential against past patterns of volatility.

Blackstone, Inc. engages in the provision of investment and fund management services. It operates through the following segments: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions. The Real Estate segment includes management of opportunistic real estate funds, Core+ real estate funds, high-yield real estate debt funds, and liquid real estate debt funds. The Private Equity segment consists of management of flagship corporate private equity funds, sector and geographically focused corporate private equity funds, core private equity funds, an opportunistic investment platform, a secondary fund of funds business, infrastructure-focused funds, a life sciences investment platform, a growth equity investment platform, a multi-asset investment program for eligible high net worth investors and a capital markets services business. The Credit and Insurance segment refers to Blackstone Credit, which is organized into two overarching strategies: private credit which includes mezzanine direct lending funds, private placement strategies, stressed and distressed strategies and energy strategies, and liquid credit which consists of CLOs, closed-ended funds, open ended funds and separately managed accounts. In addition, the segment includes an insurer-focused platform, an asset-based finance platform, and publicly traded master limited partnership investment platform. The Hedge Fund Solutions segment focuses on Blackstone Alternative Asset Management, which manages a broad range of commingled and customized hedge fund of fund solutions. It also includes a GP Stakes business and investment platforms that invest directly, as well as investment platforms that seed new hedge fund businesses and create alternative solutions through daily liquidity products. The company was founded by Stephen Allen Schwarzman in 1985 and is headquartered in New York, NY.

Blackstone Inc

Blackstone is trending as investors weigh its aggressive pivot toward private credit and AI-driven infrastructure against lingering concerns regarding industry-wide redemption pressures and valuation risks in the real estate sector. The community is sharply divided, with some betting on a long-term turnaround fueled by record dry powder and strategic deployment, while others are closely monitoring potential liquidity constraints that could signal broader credit cycle risks.

Lemonade, Inc. is a holding company, which engages in the provision of insurance services. The firm's products include renters and homeowners insurance, and pet insurance. It offers insurance coverage under the homeowners multi-peril, inland marine, and general liability lines of business. The company was founded by Daniel Asher Schreiber and Shai Wininger on June 17, 2015 and is headquartered in New York, NY.

Lemonade Inc

Lemonade is currently seeing significant momentum as investors digest its latest quarterly results, which showcased accelerating revenue growth and improved margins that suggest its AI-driven model is gaining traction. The stock remains a focal point for the retail community, who are actively debating its valuation versus its disruptive potential, while some traders continue to monitor for short-squeeze opportunities driven by high short interest and institutional interest.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is trending as investors react to the recent appointment of a new CFO and continued speculation regarding a potential hyperscaler tenant for its data center campus. Community discourse remains divided, with supporters highlighting upcoming catalysts and infrastructure scale, while skeptics point to the lack of official contract announcements and concerns over the company's delivery timeline.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is experiencing a surge in community engagement and social media momentum as supporters rally around the project's 'culture-first' branding and upcoming milestones. Investors are increasingly connecting the token to broader cannabis sector trends and shifting regulatory sentiment, positioning it as a grassroots-driven alternative within the decentralized ecosystem.

Morgan Stanley operates as a global financial services company. The firm provides investment banking products and services to its clients and customers including corporations, governments, financial institutions, and individuals. It operates through the following segments: Institutional Securities, Wealth Management, and Investment Management. The Institutional Services segment provides financial advisory, capital-raising services, and related financing services on behalf of institutional investors. The Wealth Management segment offers brokerage and investment advisory services covering various types of investments, including equities, options, futures, foreign currencies, precious metals, fixed-income securities, mutual funds, structured products, alternative investments, unit investment trusts, managed futures, separately managed accounts, and mutual fund asset allocation programs. The Investment Management segment provides equity, fixed income, alternative investments, real estate, and merchant banking strategies. The company was founded by Harold Stanley and Henry S. Morgan in 1924 and is headquartered in New York, NY.

Morgan Stanley

Morgan Stanley shares are surging following a strong third-quarter earnings report, where significant growth in investment banking fees and record-breaking wealth management results topped analyst expectations. The community is actively discussing the firm's robust trading performance and capitalizing on its strong market positioning as part of a broader rally in the financial sector.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending as investors weigh recent legal escalations against competitive rivals alongside ongoing anticipation for federal integration pilot program updates and potential defense contract awards. Community sentiment remains deeply divided, balancing concerns over high cash burn and development delays against optimism for the stock's long-term positioning in the electric aviation sector.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is trending as investors show strong conviction in its proprietary Alpha DaRT oncology platform, bolstered by recent Japanese marketing approval and upcoming trial milestones. The community is actively discussing the stock's robust cash position, the absence of dilution risk, and the belief that the company is significantly undervalued as it transitions into a commercial-stage player.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is currently experiencing a wave of market activity as investors weigh the asset's potential against broader crypto market trends and historical volatility. The community remains deeply divided, with some traders actively looking to exploit price fluctuations while long-term holders continue to debate the impact of institutional adoption, regulatory clarity, and the company's token management strategy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Protara Therapeutics, Inc. (NASDAQ:TARA) Short Interest Up 48.0% in February

Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) saw a large increase in short interest in the month of February. As of February 27th, there was short interest totaling 4,895,488 shares, an...

FY2030 Earnings Forecast for TARA Issued By HC Wainwright

Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Stock analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of Protara Therapeutics in a research note issued...

Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight research firms that are currently covering the firm...

Protara Therapeutics (NASDAQ:TARA) Now Covered by JPMorgan Chase & Co.

JPMorgan Chase & Co. started coverage on shares of Protara Therapeutics in a report on Wednesday. They issued an "overweight" rating and a $27.00 target price for the company...

Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf

Protara Therapeutics (NASDAQ:TARA) executives outlined progress across the company's two clinical-stage programs during a fireside chat at Oppenheimer's 36th Annual Healthcare Life Sciences...

Protara Therapeutics (TARA) to Release Earnings on Wednesday

Protara Therapeutics (NASDAQ:TARA) will be releasing its Q4 2025 earnings before the market opens on Wednesday, March 4. (View Earnings Report at...

Protara Therapeutics Highlights Phase 2 TARA-002 Data in NMIBC, Cites Strong Response Rates at ASCO GU

Protara Therapeutics (NASDAQ:TARA) shared updated interim data from its ongoing Phase 2, open-label ADVANCED-2 trial evaluating intravesical TARA-002 in patients with high-risk non-muscle invasive...

<ul class="summary-bullets"><li>The company reported strong efficacy and a clean safety profile from its ongoing Phase 2 Advanced-2 bladder cancer trial.</li><li>Durability signals were notable, with 68% of BCG-unresponsive patients and 66% of BCG-naive patients cancer-free at six months.</li><li>Safety and tolerability remained favorable, with mostly mild, short-lived side effects and no severe treatment-related adverse events.</li></ul>Shares of Protara Therapeutics, Inc. (TARA) fell nearly 15% in extended trading on Monday, even as the company reported strong response rates and favorable tolerability in its ongoing Phase 2 bladder cancer trial.TARA stock jumped 9% on Monday’s regular session to $7.43, hitting its highest levels in three months and its best session in nearly a month.<h2 class="st-heading-2">Phase 2 Trial Shows Strong Efficacy Signals</h2>The after-hours move followed updated interim results from Protara’s open-label Phase 2 Advanced-2 trial, which is testing TARA-002 as a bladder-delivered treatment in patients with high-risk non-muscle invasive bladder cancer. The study includes patients whose cancer has returned despite standard BCG therapy, as well as patients who have not previously received BCG, a commonly used bladder cancer treatment.Among patients whose cancer recurred after standard BCG treatment, 66% of the 35 patients evaluated achieved a complete response at some point during the study. Among those assessed at six months, 68% were cancer-free, while 33% remained cancer-free at 12 months. Statistical estimates showed a 71% probability of maintaining a complete response for at least six months, and 62% of patients who required re-treatment later achieved a complete response within six months.In patients who had not previously received BCG, 72% achieved a complete response at some point, with 66% cancer-free at six months and 58% at 12 months. Statistical estimates indicated a 73% probability of maintaining a response for at least six months, and 67% of re-treated patients achieved a complete response by six months.<h2 class="st-heading-2">Safety Profile Remains Clean</h2>The company also said the trial noted a favorable safety and tolerability profile for TARA-002. Most treatment-related adverse events were Grade 1 and transient, with no Grade 3 or higher events reported and no treatment-related serious adverse events observed. No patients discontinued treatment due to adverse events.“In addition to demonstrating impressive efficacy and safety, TARA-002 overcomes the limitations of existing NMIBC treatments that burden patients as well as urologists and their practices,” said CEO Jesse Shefferman.The most commonly reported side effects included dysuria, bladder spasm, fatigue and urinary urgency, with bladder irritation typically resolving within hours to a few days after administration.<h2 class="st-heading-2">Analysts Remain Bullish Despite Selloff</h2>Despite the after-hours decline, analyst sentiment toward the stock remains positive. Koyfin estimates show a 12-month average price target of $25.5, implying a potential upside of more than 240% from current levels.The stock carries a consensus rating of ‘Strong Buy’, with seven covering analysts. Of them, one rates the stock a ‘Strong Buy’, while six rate it ‘Buy.’<h2 class="st-heading-2">Advanced-3 Trial Planned for 2026</h2>Protara said it expects to complete enrollment in the Advanced-2 trial cohort of patients whose cancer returned after standard BCG treatment in the second half of 2026. Enrollment in the cohort of patients who had not previously received BCG is already complete, with 31 patients enrolled.The company also said it remains on track to initiate the Advanced-3 registrational trial in patients who have not previously received BCG in the second half of 2026, positioning TARA-002 for potential late-stage development across multiple high-risk non-muscle invasive bladder cancer populations.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for TARA was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/tara_ss_png_6da5855253.webp" alt="tara ss.png" width="967" height="141"><figcaption>TARA sentiment and message volume as of February 24 | Source: Stocktwits</figcaption></figure>One user said, “I am not sure why this stock did a nose dive after hours unless the results were widely misinterpreted.”<stembedurl>https://stocktwits.com/GammaRadiated/message/645688600</stembedurl>Another user said, “Don't catch this falling knife!! buy into tara low,” and added that investors can expect a profit on Tuesday.<stembedurl>https://stocktwits.com/RoadToAHouse/message/645675757</stembedurl>TARA stock has risen 40% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

TARA stock has risen 40% year to date. (Photo credit: Getty Images)

Does TARA Stock’s 15% After-Hours Slump Signal A Bargain After New Bladder Cancer Data?

The company is on track to initiate the Advanced-3 registrational trial in patients who have not previously received BCG in the second half of 2026.

Equity

Protara Therapeutics (NASDAQ:TARA) Trading Up 2.3% - Should You Buy?

Protara Therapeutics (NASDAQ:TARA) Trading Up 2.3% - Should You Buy...

Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Recommendation of "Moderate Buy" from Analysts

Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) has been given an average rating of "Moderate Buy" by the seven research firms that are covering the company, MarketBeat Ratings reports...

$TARA Q4 &#39;25 Earnings Results &amp; Recap

Protara Therapeutics expects to incur increasing operating losses for the foreseeable future, requiring additional capital to fund ongoing clinical trials and research. Protara Therapeutics believes its current financial resources are sufficient for at least 12 months.

Stocktwits

Protara Therapeutics Inc

 Q4 '25 Earnings Results & Recap

Protara Therapeutics expects to incur increasing operating losses for the foreseeable future, requiring additional capital to fund ongoing clinical trials and research. Protara Therapeutics believes its current financial resources are sufficient for at least 12 months.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.

Current Price	$5.42
Prev Close	$5.26
Open	$5.32
Dividend Yield	0.00%
50-Day Moving Average	$6.08
Beta	1.21
Avg. Volume	1.21M
PE Ratio	-3.94

52-Week High	$7.82
52-Week Low	$2.77
Market Capitalization	$284.48M
EPS (Annual)	-$1.34
Price to Book	1.44
Revenue Per Employee	$0.00

TARA
Protara Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TARA News

TARAProtara Therapeutics Inc